In the present study, we developed NOV, which exhibits the dual advantages of cancer selectivity and normal vessel reconstructive properties as a result of the expression of TRAIL and Ang1 in the place of vTk and VGF, respectively (Figure 1). The gene discussed is ANGPT1; the disease is cancer.